


# MAXIMIZE MEDICAL MANAGEMENT OF XHANCE

**XHANCE**<sup>®</sup>  
(fluticasone propionate) nasal spray 93 mcg

*XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.*

**When patients remain symptomatic after conventional intranasal steroids, choose XHANCE next in a stepped-care approach to treat nasal polyps<sup>1,2</sup>**



**When symptoms persist**



**Evidence supports use of XHANCE. It's time.<sup>3,4</sup>**

- Differentiated from conventional nasal sprays—XHANCE uses an Exhalation Delivery System that reaches high and deep in the nasal passages where nasal polyps originate<sup>1,3,4</sup>
- XHANCE is included as a treatment option distinct from conventional intranasal steroids as part of the ACAAI/ARS shared decision model<sup>2</sup>

*When symptoms persist,  
reach high and deep with XHANCE.*

## **IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS:** Hypersensitivity to any ingredient in XHANCE.

### **WARNINGS AND PRECAUTIONS:**

- Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, *Candida albicans* infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.

**Please see Important Safety Information on back and accompanying full Prescribing Information, including Instructions for Use.**

XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

## WHEN SYMPTOMS PERSIST USING CONVENTIONAL INTRANASAL STEROIDS, IT MAY BE THE TIME FOR XHANCE<sup>1,2</sup>

**XHANCE**<sup>®</sup>  
(fluticasone propionate) nasal spray 93 mcg

To learn more, go to [XHANCEhcp.com/when-to-use](https://XHANCEhcp.com/when-to-use)

### IMPORTANT SAFETY INFORMATION

**CONTRAINDICATIONS:** Hypersensitivity to any ingredient in XHANCE.

**WARNINGS AND PRECAUTIONS:**

- Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, *Candida albicans* infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.
- Close monitoring for glaucoma and cataracts is warranted.
- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
- Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.

- Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
- Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

**ADVERSE REACTIONS:** The most common adverse reactions (incidence  $\geq$  3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

**DRUG INTERACTIONS:** Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

**USE IN SPECIFIC POPULATIONS:** Hepatic impairment. Monitor patients for signs of increased drug exposure.

**References:** **1.** American Rhinologic Society. Nasal Polyps. SINUSHEALTH website. <https://sinushealth.com/conditions/treatment-of-nasal-polyps/>. Accessed February 8, 2021. **2.** American Rhinologic Society and American College of Allergy, Asthma and Immunology. Treating Chronic Rhinosinusitis with Nasal Polyps Shared Decision-Making Tool. American College of Allergy, Asthma and Immunology. 2020. [https://www.american-rhinologic.org/index.php?option=com\\_content&view=article&id=374:nosenews-sept-2020&catid=61:newsletter-archive#CRSwNPTool](https://www.american-rhinologic.org/index.php?option=com_content&view=article&id=374:nosenews-sept-2020&catid=61:newsletter-archive#CRSwNPTool). Accessed March 22, 2021. **3.** Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2021. **4.** Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. *J Allergy Clin Immunol.* 2019;143(1):126-134.

Please see full accompanying Prescribing Information, including Instructions for Use.

